{"result": "(\"entity\"<|>MDTEXT.COM, INC.<|>ORGANIZATION<|>MDText.com, Inc. is a publisher based in South Dartmouth, MA, known for providing medical information and guidelines.)\n##\n(\"entity\"<|>ENDOCRINE SOCIETY<|>ORGANIZATION<|>The Endocrine Society is a professional organization that publishes clinical practice guidelines, including those for the evaluation and treatment of hirsutism.)\n##\n(\"entity\"<|>J CLIN ENDOCRINOL METAB<|>ORGANIZATION<|>J Clin Endocrinol Metab is a medical journal that publishes research and guidelines related to endocrinology.)\n##\n(\"entity\"<|>SÍNDROME DE OVARIO POLIQUÍSTICO<|>EVENT<|>Síndrome de ovario poliquístico (SOP) is a medical condition characterized by hormonal imbalance in women, leading to various symptoms including hirsutism and irregular menstrual cycles.)\n##\n(\"entity\"<|>MARTIN KA<|>PERSON<|>Martin KA is a medical professional involved in the evaluation and treatment of hirsutism, as indicated in the clinical practice guideline.)\n##\n(\"entity\"<|>ANDERSON RR<|>PERSON<|>Anderson RR is a medical professional who contributed to the clinical practice guideline on hirsutism.)\n##\n(\"entity\"<|>CHANG RJ<|>PERSON<|>Chang RJ is a medical professional who contributed to the clinical practice guideline on hirsutism.)\n##\n(\"entity\"<|>EHRMANN DA<|>PERSON<|>Ehrmann DA is a medical professional who contributed to the clinical practice guideline on hirsutism.)\n##\n(\"entity\"<|>LOBO RA<|>PERSON<|>Lobo RA is a medical professional who contributed to the clinical practice guideline on hirsutism.)\n##\n(\"entity\"<|>MURAD MH<|>PERSON<|>Murad MH is a medical professional who contributed to the clinical practice guideline on hirsutism.)\n##\n(\"entity\"<|>ORTIZ-FLORES AE<|>PERSON<|>Ortiz-Flores AE is a medical professional who authored a paper on síndrome de ovario poliquístico in adult women.)\n##\n(\"entity\"<|>LUQUE-RAMÍREZ M<|>PERSON<|>Luque-Ramírez M is a medical professional who authored a paper on síndrome de ovario poliquístico in adult women.)\n##\n(\"entity\"<|>ESCOBAR-MORREALE HF<|>PERSON<|>Escobar-Morreale HF is a medical professional who authored a paper on síndrome de ovario poliquístico in adult women.)\n##\n(\"relationship\"<|>MARTIN KA<|>ENDOCRINE SOCIETY<|>Martin KA is a contributor to the Endocrine Society's clinical practice guideline on hirsutism<|>7)\n##\n(\"relationship\"<|>ANDERSON RR<|>ENDOCRINE SOCIETY<|>Anderson RR is a contributor to the Endocrine Society's clinical practice guideline on hirsutism<|>7)\n##\n(\"relationship\"<|>CHANG RJ<|>ENDOCRINE SOCIETY<|>Chang RJ is a contributor to the Endocrine Society's clinical practice guideline on hirsutism<|>7)\n##\n(\"relationship\"<|>EHRMANN DA<|>ENDOCRINE SOCIETY<|>Ehrmann DA is a contributor to the Endocrine Society's clinical practice guideline on hirsutism<|>7)\n##\n(\"relationship\"<|>LOBO RA<|>ENDOCRINE SOCIETY<|>Lobo RA is a contributor to the Endocrine Society's clinical practice guideline on hirsutism<|>7)\n##\n(\"relationship\"<|>MURAD MH<|>ENDOCRINE SOCIETY<|>Murad MH is a contributor to the Endocrine Society's clinical practice guideline on hirsutism<|>7)\n##\n(\"relationship\"<|>ORTIZ-FLORES AE<|>SÍNDROME DE OVARIO POLIQUÍSTICO<|>Ortiz-Flores AE authored a paper discussing the condition of síndrome de ovario poliquístico<|>6)\n##\n(\"relationship\"<|>LUQUE-RAMÍREZ M<|>SÍNDROME DE OVARIO POLIQUÍSTICO<|>Luque-Ramírez M authored a paper discussing the condition of síndrome de ovario poliquístico<|>6)\n##\n(\"relationship\"<|>ESCOBAR-MORREALE HF<|>SÍNDROME DE OVARIO POLIQUÍSTICO<|>Escobar-Morreale HF authored a paper discussing the condition of síndrome de ovario poliquístico<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK278959/ (Updated 2017 Jan 11).\n- Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(4):1233-57. https://doi.org/10.1210/jc.2018-00241\n- Ortiz-Flores AE, Luque-Ramírez M, Escobar-Morreale HF. Síndrome de ovario poliquístico en la mujer adulta. Med Clin (Barc) [Internet]. 2019;152(11):450-7.\n\n19 Una paciente de 28 años es enviada por su médico de primaria por hirsutismo lentamente progresivo desde su menarquía a los 12 años. La intensidad del vello puntuada por la escala de Ferriman-Gallwey es de 18 puntos. Las reglas son irregulares, con una media de 6-7 reglas por año. Dice presentar acné importante, pero nosotros solo apreciamos 4 lesiones inflamatorias en cara y otras tantas en espalda. Presenta sobrepeso desde la menarquia, que ha ido aumentando de forma gradual (actualmente su IMC es de 31,6). Usted sospecha síndrome de ovario poliquístico (SOP). ¿Cuál de las siguientes afirmaciones es falsa en esta paciente?\n\nA. Para poder ser diagnosticada de SOP por los criterios de Rotterdam debe cumplir los tres criterios siguientes: oligo/anovulación + hiperandrogenismo (clínico o bioquímico) + ovarios poliquísticos visualizados en eco. Por lo tanto, hay que pedir ecografía abdominal.\nB. En la mayoría de las guías se recomienda como principal determinación analítica la testosterona total.\nC. Para diagnosticar SOP es importante haber excluido primero otros trastornos que puedan cursar con hiperandrogenismo y oligomenorrea/amenorrea, como pueden ser la hiperplasia suprarrenal congénita, la disfunción tiroidea o la hiperprolactinemia.\nD. Si se confirma SOP hay que prestar vigilancia a otros factores de riesgo cardiovascular además de su obesidad, como son la intolerancia a la glucosa, la dislipidemia, el hígado graso y el síndrome de apneas del sueño.\n\nCOMENTARIO\n\nEl diagnóstico de SOP requiere al menos dos de los siguientes criterios de Rotterdam, en ausencia de otras enfermedades que cursen con hiperandrogenismo o clínica similar:\n\n1. Hiperandrogenismo clínico o bioquímico. El hirsutismo es la manifestación más frecuente y es considerado el signo más indicativo de hiperandrogenismo clínico. Se considera patológico de forma general en la población femenina un nivel de corte de 8 puntos en la escala de Ferriman-Gallwey modificada, y específicamente para la población española, de 10. El andrógeno de mayor potencia, interés y utilidad para definir el hiperandrogenismo bioquímico sería la testosterona libre, pero su determinación no siempre está disponible ni tiene la necesaria fiabilidad, por lo que se acepta la determinación de la testosterona total como principal determinación, corrigiéndola para las cifras de SHBG (índice androgénico libre = testosterona total × 100/SHBG). Es frecuente que se encuentren también aumentados otros andrógenos (DHEA-S y 4A).\n\n2. Anovulación. La disfunción ovulatoria en pacientes en edad fértil viene definida por oligomenorrea (menos de 8 periodos menstruales en un año) o amenorrea (falta de periodos menstruales durante más de 3 meses en ausencia de embarazo), pudiendo también incluirse ciclos mayores de 35 días, polimenorrea (ciclos de menos de 21 días) o situaciones de anovulación con reglas normales.\n\n3. Morfología de ovario poliquístico en ecografía. La ecografía ovárica debe recoger los detalles necesarios para determinar la morfología característica del SOP, que\n---\n# GÓNADAS, SÍNDROME POLIGLANDULAR AUTOINMUNE Y MISCELÁNEA\n\nson 12 o más folículos en cada ovario de 2 a 9 mm y/o aumento de volumen ovárico mayor de 10 ml.\n\nMediante la anamnesis y otras pruebas complementarias debe demostrarse a priori la ausencia de otras enfermedades que cursen con hiperandrogenismo o clínica similar al ovario poliquístico, como la oligoamenorrea, el uso de medicamentos androgenizantes, la determinación de 17-OH-progesterona, el cortisol libre urinario (CLU) o salival, la prolactina\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}